{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.2","upperLimit":"71.4","value":"63.1"},{"groupId":"OG001","lowerLimit":"51.6","upperLimit":"89.8","value":"73.9"},{"groupId":"OG002","lowerLimit":"69.2","upperLimit":"85.7","value":"78.3"},{"groupId":"OG003","lowerLimit":"43.2","upperLimit":"69.4","value":"56.7"},{"groupId":"OG004","lowerLimit":"66.4","upperLimit":"86.7","value":"77.8"},{"groupId":"OG005","lowerLimit":"66.3","upperLimit":"95.8","value":"85.2"},{"groupId":"OG006","lowerLimit":"27.5","upperLimit":"66.1","value":"46.4"},{"groupId":"OG007","lowerLimit":"5.4","upperLimit":"41.9","value":"19.0"},{"groupId":"OG008","lowerLimit":"0.99","upperLimit":"36.0","value":"7.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"106"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"72"},{"groupId":"OG005","value":"27"},{"groupId":"OG006","value":"28"},{"groupId":"OG007","value":"21"},{"groupId":"OG008","value":"13"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) for at least two assessments with at least 28 days apart and no disease progression (PD) in between. Per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in the short axis to \\<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline). ORR and its two-sided 95% CI, based on the exact binomial distribution (Clopper-Pearson), were presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who had RET-fusion positive NSCLC previously treated with platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG000","title":"RET- Fusion Positive NSCLC With Prior Platinum Treatment:"},{"description":"Participants who had RET-fusion positive NSCLC previously treated with non-platinum or systemic therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG001","title":"RET-fusion Positive NSCLC With Non-platinum Systemic Treatment"},{"description":"Participants who had RET-fusion positive NSCLC not previously treated with systemic or platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG002","title":"RET-fusion Positive NSCLC With No Prior Systemic or Platinum Treatment"},{"description":"Participants who had RET- mutation positive MTC previously treated with either cabozantinib and/or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG003","title":"RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment"},{"description":"Participants who had RET- mutation positive MTC not previously treated with cabozantinib or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG004","title":"RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment"},{"description":"Participants who had RET-fusion positive TC received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG005","title":"RET-fusion Positive TC"},{"description":"Participants who had other RET-positive solid tumors other than NSCLC and TC received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG006","title":"RET-fusion Positive Solid Tumors Other Than NSCLC and TC"},{"description":"Participants who had RET-altered (fusion or mutation) solid tumors previously treated with a selective RET tyrosine kinase inhibitor (TKI) received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG007","title":"RET-altered Solid Tumors Previously Treated With RET Inhibitor"},{"description":"Participants who had RET-mutation positive solid tumors received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG008","title":"RET-mutation Positive Tumors Other Than MTC"}],"paramType":"NUMBER","populationDescription":"RET-altered measurable disease population included participants in the efficacy population who had measurable (target) disease per RECIST v1.1 at baseline according to blinded central review (BICR) and sufficient evidence of a RET alteration. As prespecified in the SAP, Phase 1 participants treated at 400 mg QD are also included in Phase 2 efficacy analysis.","reportingStatus":"POSTED","timeFrame":"Up to approximately 79.8 months","title":"Phase 2: Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}